Boundless Bio, Inc. (BOLD)
2.63
+0.01
(+0.38%)
USD |
NASDAQ |
Oct 05, 13:12
Boundless Bio Shareholders Equity (Quarterly) : 65.98M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 65.98M |
| March 31, 2026 | 86.38M |
| December 31, 2025 | 98.65M |
| September 30, 2025 | 110.17M |
| June 30, 2025 | 122.69M |
| March 31, 2025 | 136.59M |
| December 31, 2024 | 150.64M |
| September 30, 2024 | 165.08M |
| Date | Value |
|---|---|
| June 30, 2024 | 179.25M |
| March 31, 2024 | 106.43M |
| December 31, 2023 | -127.08M |
| September 30, 2023 | -116.04M |
| June 30, 2023 | -103.87M |
| March 31, 2023 | |
| December 31, 2022 | -81.70M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
| Biogen, Inc. | 18.85B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 73.74M |
| Total Liabilities (Quarterly) | 7.768M |
| Current Ratio | 9.481 |
| Net Debt Paydown Yield | 17.29% |